Nirmatrelvir ni inhibitori ya protease nyamukuru ya SARS-CoV-2 (Mpro), nanone yitwa protease isa na 3C (3CLpro) cyangwa protease nsp5. Kubuza SARS-CoV-2 Mpro bituma idashobora gutunganya polyproteine ​​ibanziriza, ikumira virusi.

Nirmatrelvir yabujije ibikorwa bya recombinant SARS-CoV-2 Mpro mu isuzuma ryibinyabuzima ryibinyabuzima bigera kuri vivo. Nirmatrelvir wasangaga ihuza neza na SARS-CoV-2 Mpro urubuga rukora na X-ray kristallografiya.

Ritonavir ni virusi ya virusi ya VIH-1 ariko ntabwo ikora kurwanya SARS-CoV-2 Mpro. Ritonavir irabuza CYP3A-yunganirwa na metabolism ya nirmatrelvir, bigatuma plasma yiyongera kuri nirmatrelvir.

Uyu muti urasabwa. Yahawe uruhushya rwo gukoresha byihutirwa na FDA mu kuvura indwara ya coronavirus yoroheje-yoroheje (COVID-19) ku bantu bakuru ndetse n’abarwayi b’abana (imyaka 12 nayirenza ipima byibura ibiro 40 cyangwa hafi ibiro 88) hamwe ibisubizo byiza byo kwipimisha SARS-CoV-2 itaziguye, kandi bafite ibyago byinshi byo kuzamuka kuri COVID-19 ikabije, harimo ibitaro cyangwa urupfu. Nirmatrelvir / ritonavir igomba gutangizwa vuba bishoboka nyuma yo gusuzuma COVID-19 kandi mugihe cyiminsi itanu ibimenyetso bitangiye.

Ibyifuzo bishingiye kuri EPIC-HR, Phase2 / 3 igeragezwa ryigenzura ryamavuriro ryerekana ingaruka za nirmaltrelivir / ritonavir na placebo mukugabanya ibitaro cyangwa urupfu kugeza kumunsi wa 28. Gukoresha nirmaltrelivir / ritonavir mugihe cyiminsi 5 ibimenyetso bitangiye. abantu bafite ibyago byo kwandura indwara zikomeye bagabanije ibyago byo kuba mubitaro cyangwa gupfa muminsi 28 kuri 88%.